Stockreport

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts [Seeking Alpha]

Lyell Immunopharma, Inc.  (LYEL) 
PDF The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has upcoming data catalysts, with Phase 1 results expected in the fi [Read more]